Erasca, Tango Therapeutics Launch Phase 1/2 Cancer Drug Trial
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
01:38:31 PM UTC
SquawkNews
Tango Therapeutics and Erasca opened enrollment in a Phase 1/2 study of vopimetostat with ERAS-0015 for MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant NSCLC. The trial will assess dose, safety and antitumor activity.Material DetailsContext by AI AnalystThis is an early-stage clinical de…